Evidence map›Paper›PMID 11551376›Full record

ReviewCurrent hypertension reports2001

Use of gene markers to guide antihypertensive therapy.

S T Turner, G L Schwartz, A B Chapman, E Boerwinkle

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005520 (Genetic Epidemiology of Responses to Antihypertensives), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00005520 completednot on this map

Genetic Epidemiology of Responses to Antihypertensives

TypeobservationalSponsorMayo ClinicRan1997 to 2008Enrolled1,200ConditionsCardiovascular Diseases, Heart Diseases, HypertensionArmsHydrochlorothiazide, Candesartan
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Gene markers and antihypertensive therapy.Current hypertension reports · 2005
    Review
  2. Remission and regression of diabetic nephropathy.Current hypertension reports · 2004
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S T TurnerDivision of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, 200 First Street S.W., Rochester, MN 55905, USA. turner.stephen@mayo.edu
G L Schwartz
A B Chapman
E Boerwinkle
Mayo Clinic · US

Funding

GENETIC EPIDEMIOLOGY OF RESPONSES TO ANTIHYPERTENSIVESR01HL053330 · NHLBI · MAYO CLINIC ROCHESTER · PI TURNER, STEPHEN T · 1997 to 2006
$5.5M
GENETIC DETERMINANTS OF HIGH BP IN THREE RACIAL GROUPSU10HL054464 · NHLBI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI TURNER, STEPHEN T · 1995 to 1999
–
NHLBI NIH HHS R01 HL53330NHLBI NIH HHS U10 HL54464
6 · The paper itself

Abstract

Sequencing of the human genome has elevated the potential for genetic information to aid in the prevention, diagnosis, and treatment of common chronic diseases. One beneficial application of genetic information is the identification of variants that influence response to pharmaceutical agents used to lower blood pressure and prevent target organ complications of hypertension. Knowledge of genetic variants that influence blood pressure response to antihypertensive drugs may allow more individualized tailoring of antihypertensive drug therapy, and provide greater insight into the molecular mechanisms regulating blood pressure levels and causing hypertension.

Indexed as

Antihypertensive AgentsBlood PressureDose-Response Relationship, DrugForecastingGenetic MarkersHumansHypertensionAntihypertensive AgentsGenetic Markers

Identifiers

PMID11551376
OpenAlexW1998027080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.